International journal of cardiology最新文献

{"title":"Coronary calcifications are the growth rings of coronary atherosclerotic plaque","authors":"Michele Russo , Marco Zimarino","doi":"10.1016/j.ijcard.2025.133902","DOIUrl":"10.1016/j.ijcard.2025.133902","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133902"},"PeriodicalIF":3.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Reconsidering thyroid hormone assessment in heart failure risk prediction\".","authors":"Jia-Meng Ren, Yuan-Gengshuo Wang, Ji-Lin Zheng, Wen-Yao Wang, Yi-da Tang","doi":"10.1016/j.ijcard.2025.133912","DOIUrl":"10.1016/j.ijcard.2025.133912","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":" ","pages":"133912"},"PeriodicalIF":3.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of readmission by intensified follow-up after transcatheter aortic valve implantation: Feasibility results of the PREMISS randomised controlled trial","authors":"Bettina Højberg Kirk ,&nbsp;Pernille Palm ,&nbsp;Marianne W. Nørgaard ,&nbsp;Britt Borregaard ,&nbsp;Tone M. Norekvål ,&nbsp;Ole De Backer","doi":"10.1016/j.ijcard.2025.133894","DOIUrl":"10.1016/j.ijcard.2025.133894","url":null,"abstract":"<div><h3>Background</h3><div>Hospital readmissions after transcatheter aortic valve implantation (TAVI) are common. This study aimed to investigate the feasibility and impact of an intensified follow-up intervention on cardiac readmissions, mortality, and self-reported health status post-TAVI.</div></div><div><h3>Methods</h3><div>The study was designed as a randomised controlled trial to compare an early follow-up intervention with standard care. The intervention included tailored telephone and in-hospital consultations within 30 days post-TAVI. The feasibility outcomes were enrolment, attrition, and completion rates. Efficacy outcomes included all-cause mortality, cardiac-related hospital readmissions, and self-reported health status at 30 and 90 days after TAVI.</div></div><div><h3>Results</h3><div>Eighty patients were randomised to either the intensified or standard follow-up. The intervention was feasible, achieving a 73 % recruitment rate (target &gt;50 %), 0 % attrition, 93 % questionnaire completion, and 100 % follow-up during the 30-day intervention and 90-day follow-up period. Detailed insights into processes, resources, management, and scientific approach of the intervention were provided. There was no mortality within 90 days in both groups. Cardiac readmissions within 90 days were 11 (28 %) in the standard care group vs 4 (10 %) in the intervention group (<em>p</em> = 0.04); this difference was mostly driven by short (&lt;24-h) cardiac readmissions in the early post-TAVI period (13 % vs 0 %, respectively). Early improvements in self-reported health status occurred in both groups with no significant differences between groups.</div></div><div><h3>Conclusion</h3><div>An intensified follow-up intervention combining telephone and outpatient consultations after discharge from TAVI was shown to be feasible with high recruitment and completion rates. This study indicates that an intensified follow-up post-TAVI may prevent early cardiac readmissions.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133894"},"PeriodicalIF":3.2,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of discontinuation and non-publication of heart failure clinical trials: A cross-sectional analysis of ClinicalTrials.gov data","authors":"Mohmmad M. Alawajneh ,&nbsp;Ahmed Aljabali ,&nbsp;Laith Theeb ,&nbsp;Shaden Tashtoush ,&nbsp;Sakhr Alshwayyat ,&nbsp;Ayah Bani Mostafa ,&nbsp;Laith Alhuneafat ,&nbsp;Claudio Laudani ,&nbsp;Ahmed M. Altibi","doi":"10.1016/j.ijcard.2025.133901","DOIUrl":"10.1016/j.ijcard.2025.133901","url":null,"abstract":"<div><div>Heart failure (HF) is a major public health challenge that depends on continuous clinical research to guide care. However, the frequent discontinuation and nonpublication of HF trials may impede scientific progress and limit the impact of research efforts.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis using <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> to determine all completed, discontinued, or published HF clinical trials (January 2000–June 2022). For each trial, data on the trial phase, funding source, intervention type, enrollment, trial completion, and publication status were extracted. Logistic regression was used to identify predictors of trial completion and publication.</div></div><div><h3>Results</h3><div>Of the 1181 HF trials identified, 288 (24.3 %) were discontinued. Among the 893 completed trials (75.6 %), 344 (38.5 %) remained unpublished. Trials with ≥100 participants were less likely to be discontinued (OR 0.25; 95 % CI 0.17–0.36; <em>P</em> &lt; 0.01) and more likely to be published (OR 2.10; 95 % CI 1.47–3.03; <em>P</em> &lt; 0.001). Trials exclusively involving females (compared to male-only trials) had a higher likelihood of discontinuation (OR 52.29 [5.07–1332.01], <em>p</em> &lt; 0.01), though no significant association with publication status. Randomized trials (OR 2.16; 95 % CI 1.06–4.43; <em>P</em> = 0.04) and quadruple-blinded trials (OR 0.54; 95 % CI 0.34–0.86; <em>P</em> = 0.01) were more likely to be discontinued; however, if completed, they were less likely to remain unpublished (OR 0.51, 95 % CI 0.29–0.88, <em>p</em> = 0.02; and OR 0.42, 95 % CI 0.26–0.67, <em>p</em> &lt; 0.001, respectively). Behavioral interventions were less likely to be discontinued (OR 0.11, 95 % CI 0.01, 0.55; <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Many HF trials are discontinued or unpublished, limiting the impact of participant contribution. Greater efforts to publish results can help ensure these contributions advance research and reduce bias.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133901"},"PeriodicalIF":3.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Echocardiographic AMYLI score in systemic light-chain amyloidosis: Clinical relevance and risk stratification","authors":"Shichu Liang ,&nbsp;Keying Bi ,&nbsp;Ke Wan ,&nbsp;Zhiyue Liu ,&nbsp;Yaqiong Zhou ,&nbsp;Saeed Abdulmalek Ahmed Ghaithan ,&nbsp;Jiayu Sun ,&nbsp;Yuchi Han ,&nbsp;He Huang ,&nbsp;Yucheng Chen","doi":"10.1016/j.ijcard.2025.133889","DOIUrl":"10.1016/j.ijcard.2025.133889","url":null,"abstract":"<div><h3>Background</h3><div>The AMYLoidosis Index (AMYLI) is widely used for screening cardiac amyloidosis, but its relationship with amyloid burden and prognostic value is unclear.</div></div><div><h3>Methods</h3><div>This single-center, prospective, observational study was conducted from November 2011 to September 2023. Consecutive patients with newly-diagnosed biopsy-proven light-chain (AL) amyloidosis patients who underwent both echocardiography and cardiac magnetic resonance (CMR) were enrolled. The AMYLI score was calculated as the product of relative wall thickness (RWT) and E/e' via transthoracic echocardiography.</div></div><div><h3>Results</h3><div>A total of 263 AL amyloidosis patients (mean age 58.84 ± 9.63 years, 158 [60.1 %] males) were included in the study. The AMYLI score showed a moderately positive correlation with CMR-derived amyloid burden (extracellular volume; <em>r</em> = 0.57, <em>P</em> &lt; 0.001). During a median follow-up of 42 (interquartile range: 35–49) months, 3 patients were lost to follow-up, and 171 patients died. An AMYLI score ≥ 7.85 strongly predicted all-cause mortality (HR 2.80, 95 % CI: 1.80–4.35, <em>P</em> &lt; 0.001) and remained an independent prognostic factor after adjusting for clinical, biochemical, echocardiographic, CMR imaging-related, and therapeutic factors. AMYLI score ≥ 7.85 added incremental prognostic value to conventional clinical and imaging risk factors.</div></div><div><h3>Conclusions</h3><div>The AMYLI score is a reliable indicator of amyloid burden in patients with AL amyloidosis and independent prognostic factor, offering an alternative and convenient echocardiography-based imaging marker for the risk stratification of AL amyloidosis patients.</div></div><div><h3>Trial registration</h3><div>Chinese Clinical Trial Registry, ChiCTR1900024764 by the ethics committee of West China Hospital, Sichuan University.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133889"},"PeriodicalIF":3.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-evaluating composite CRP-based ratios in chronic heart failure: clarity beyond novelty.","authors":"Li Li","doi":"10.1016/j.ijcard.2025.133899","DOIUrl":"10.1016/j.ijcard.2025.133899","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":" ","pages":"133899"},"PeriodicalIF":3.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of post discharge virtual cardiac remote monitoring for patients with acute coronary syndrome during HAJJ season 1445H- KAMC experience","authors":"Sheeren Khaled ,&nbsp;Wael Tantawi ,&nbsp;Walaa Eldeen Ahmed ,&nbsp;Mohammed Shaikh ,&nbsp;Awad Alkhatib ,&nbsp;Areej Bahattab ,&nbsp;Roaya Buqis ,&nbsp;Mirshad Thirumangalath ,&nbsp;Hadzmer Benito ,&nbsp;Adel A. Tash ,&nbsp;Mohamed Marei ,&nbsp;Mahmoud Fawzy ,&nbsp;Hany Said ,&nbsp;Sumayyah Asiri ,&nbsp;Reem Alagmi ,&nbsp;Shahad abahussein ,&nbsp;Ahmed Fadel ,&nbsp;Rasha Alaraby ,&nbsp;Khalid Kamal","doi":"10.1016/j.ijcard.2025.133900","DOIUrl":"10.1016/j.ijcard.2025.133900","url":null,"abstract":"<div><h3>Objective</h3><div>Acute coronary syndrome (ACS) is the leading cause of death during Hajj. We evaluated a virtual monitoring system to enhance care, enable earlier discharge, and reduce readmissions.</div></div><div><h3>Method</h3><div>The current study is a prospectively collected data from 100 consecutive ACS patients who were admitted at our institution during the 2 weeks of the Hajj season 1445H.</div></div><div><h3>Result</h3><div>The mean age of our population was 57.2 ± 10.8 years; more than two-thirds were males, 29 % were non-Arabic speakers with variable-associated morbidities (51 %, 52 %, 32 %, and 30 % for DM, HTN, smoking, and dyslipidemia, respectively). More than a third of patients (43 %) fulfilled the criteria of STEMI, 14 % had severe LV systolic dysfunction in their echocardiogram, and (Bauer et al., 2022 21)% had multivessel disease in the index angiogram. Regarding intervention, 64 % underwent PCI (10 % needed staged procedure), CABG was done in 11 %, and device therapy was utilized in 4 % of cases. Implementing a remote mentoring approach during the hajj crisis facilitated the early discharge of ACS patients (78 % and 14 % within 3 and 5 days, respectively) and this was reflected in a reduced rate of readmission and ED attendance ((Shimemeri and Abdullah., 2012 1)% and 4 % respectively) with close management of patient-reported symptoms.</div></div><div><h3>Conclusions</h3><div>RPM appears safe and cost-effective for post-discharge ACS care during Hajj, reducing readmissions and hospital burden. However, the absence of a contemporaneous control group limits causal inference, and outcomes are compared to historical benchmarks. Despite this limitation, the study provides novel, prospective evidence supporting the feasibility and impact of RPM in a mass-gathering setting.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133900"},"PeriodicalIF":3.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor Reply to IPE eligibility post-ACS: Clarifying treatment gaps and refining lipid-based risk assessment.","authors":"Loukianos S Rallidis, Donatos Tsamoulis, Konstantinos A Papathanasiou","doi":"10.1016/j.ijcard.2025.133893","DOIUrl":"10.1016/j.ijcard.2025.133893","url":null,"abstract":"","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":" ","pages":"133893"},"PeriodicalIF":3.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anabolic-androgenic steroids on cardiac structure and function in resistance-trained athletes: A systematic review and meta-analysis","authors":"Douglas Nunes Cavalcante ,&nbsp;Livia Romariz ,&nbsp;Altair Neto ,&nbsp;Gustavo Eduardo Fante ,&nbsp;Silvio Marques Póvoa Júnior ,&nbsp;Caroline Fischer Bacca","doi":"10.1016/j.ijcard.2025.133896","DOIUrl":"10.1016/j.ijcard.2025.133896","url":null,"abstract":"<div><h3>Background</h3><div>Anabolic-androgenic steroids (AAS) are widely used by resistance-trained athletes, but their effects on cardiac structure and function remain uncertain.</div></div><div><h3>Objective</h3><div>To assess the impact of AAS on cardiac structure and function using echocardiography.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis to assess the effects of AAS on echocardiographic parameters in athletes, using a random-effects model and Review Manager 5.4.1.</div></div><div><h3>Results</h3><div>We included 35 studies with 2000 male individuals (834 resistance-trained athletes using AAS vs 754 resistance-trained non-users vs 412 sedentary controls; mean age 32 years). Compared with non-users of AAS, AAS users was associated with a decrease in left ventricular (LV) ejection fraction (MD -2.25 %; 95 % CI -3.41 to −1.09; <em>p</em> &lt; 0.01), and global longitudinal strain (GLS) (MD 3.34 %; 95 % CI 2.93 to 3.76; p &lt; 0.01). Athletes who used AAS also had an increased septal wall thickness (MD 1.24 mm; 95 % CI 0.79 to 1.69; p &lt; 0.01), posterior wall thickness (MD 1.09 mm; 95 % CI 0.70 to 1.48; p &lt; 0.01) and LV mass (MD 13.29 g; 95 % CI 6.25 to 20.33; p &lt; 0.01). LV end-diastolic diameter was also higher among AAS users (MD 1.09 mm; 95 % CI 0.44 to 1.73; p &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>Among athletes, AAS was associated with a significant decrease in LV ejection fraction and GLS, alongside with increased septal and posterior wall thickness, LV mass, and end-diastolic diameter compared with athletes who do not use AAS. These findings suggest adverse cardiac remodeling in AAS users, highlighting the potential harmful cardiovascular effects of steroid use in athletes.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133896"},"PeriodicalIF":3.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for myocardial infarction in patients with peripheral artery disease","authors":"Karsten Keller ,&nbsp;Volker H. Schmitt ,&nbsp;Lukas Hobohm ,&nbsp;Christine Espinola-Klein","doi":"10.1016/j.ijcard.2025.133898","DOIUrl":"10.1016/j.ijcard.2025.133898","url":null,"abstract":"<div><h3>Background</h3><div>Peripheral artery disease (PAD) is a worldwide major health problem characterized by a reduced blood flow in the arteries of the lower limbs due to obstructive atherosclerosis. PAD is afflicted by a high risk for adverse events of the limbs, but also by cardiovascular events such as myocardial infarction (MI).</div></div><div><h3>Methods</h3><div>The German nationwide inpatient statistics was used for this study. All patient-cases of patients admitted due PAD in Germany 2005–2020 were included and stratified for occurrence of MI.</div></div><div><h3>Results</h3><div>Overall, 2,825,765 patient-cases of patients admitted due to PAD were included in our study 2005–2020. Among these, 24,072 PAD patients (0.9 %) were afflicted by MI. PAD patients with MI were older (proportion of patients aged ≥70 years: 69.6 % vs. 54.2 %, <em>P</em> &lt; 0.001) and revealed an aggravated comorbidity profile. In-hospital case-fatality rate was more than 10-fold increased driven by MI (29.0 % vs. 2.7 %, <em>P</em> &lt; 0.001).</div><div>Age ≥ 70 years (OR 1.193 [95 %CI 1.158–1.229], <em>P</em> &lt; 0.001), diabetes mellitus (OR 1.405 [95 %CI 1.369–1.442], <em>P</em> &lt; 0.001), hyperlipidaemia (OR 1.099 [95 %CI 1.069–1.129], <em>P</em> &lt; 0.001), COPD (OR 1.105 [95 %CI 1.064–1.148], <em>P</em> &lt; 0.001), kidney disease (OR 1.857 [95 %CI 1.806–1.910], <em>P</em> &lt; 0.001), heart failure (OR 4.907 [95 %CI 4.769–5.048], <em>P</em> &lt; 0.001), atrial fibrillation/flutter (OR 1.177 [95 %CI 1.142–1.213], <em>P</em> &lt; 0.001), cancer (OR 1.343 [95 %CI 1.242–1.451], P &lt; 0.001) and pneumonia (OR 5.214 [95 %CI 5.021–5.414], P &lt; 0.001) were independently associated with MI.</div></div><div><h3>Conclusions</h3><div>MI occurred in 0.9 % of the PAD patients and was afflicted by more than 10-fold increased case-fatality. Independent risk factors for MI events in patients admitted due to PAD comprised age ≥ 70 years, diabetes mellitus, hyperlipidaemia, lung diseases, and cancer.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"442 ","pages":"Article 133898"},"PeriodicalIF":3.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}